跳到正文
PR Newswire 健康·· 12 天前精选AI 评分71

甘李药业 GRADUAL-3 IIIb 期研究达到主要终点,每月一次 bofanglutide 维持治疗 24 周控制体重

A New Paradigm for Long-Term Weight Management: Once-Monthly Bofanglutide Maintenance Therapy Delivers Positive Results in Weight Control and Maintenance Over 24 Weeks -- Gan & Lee Pharmaceuticals' GRADUAL-3 Study Meets Its Primary Endpoint

AI 导读

甘李药业公布 GRADUAL-3 IIIb 期研究达到主要终点:在 GRADUAL-1 中完成 52 周每两周一次 bofanglutide 治疗的肥胖或超重受试者,转为每月一次维持治疗 24 周后,体重较基线平均变化为 0.41%(24 mg)和 −0.12%(48 mg),安慰剂组为 8.52%(两者 P<0.0001)。

推荐理由

GRADUAL-3 给出了从每两周给药转为每月一次维持治疗的随机对照数据,可用于判断减重疗法长期用药的节奏安排。

正文 · 原文

, /PRNewswire/ -- Gan & Lee Pharmaceuticals (Stock Code: 603087. SH) announced positive topline results from GRADUAL-3, a Phase III clinical study evaluating once-monthly administration of its independently developed glucagon-like peptide-1 receptor agonist (GLP-1 RA), bofanglutide injection, in Chinese participants with obesity or overweight.

Figure 1. Study Flowchart

Figure 1. Study Flowchart

GRADUAL-3 is the first completed Phase IIIb sequential study globally to evaluate the maintenance of weight-loss efficacy with once-monthly administration using a randomized controlled trial (RCT) design. The study was designed to evaluate the efficacy and safety of transitioning patients from an intensive treatment regimen of bofanglutide administered once every two weeks for 52 consecutive weeks to a once-monthly regimen for weight maintenance.

GRADUAL-3 is a Phase IIIb maintenance study based on the GRADUAL-1 trial. Participants with obesity or overweight who completed 52 weeks of treatment with bofanglutide administered once every two weeks in GRADUAL-1 and met the eligibility criteria were enrolled. Participants were randomized, according to their last administered dose (24 mg or 48 mg), to receive either bofanglutide or placebo once monthly for 24 weeks.

The primary endpoint was the percentage change in body weight from baseline after 24 weeks of treatment.

After 24 weeks of treatment, the mean percentage changes in body weight from baseline were 0.41% and −0.12% in the bofanglutide 24 mg and 48 mg once-monthly groups, respectively, compared with 8.52% in the placebo group (both P<0.0001).

These results demonstrate that, following substantial weight loss achieved with 52 weeks of bofanglutide administered once every two weeks, transitioning to once-monthly administration can effectively prevent weight regain following discontinuation of the intensive treatment regimen and maintain previously achieved weight-loss benefits. This study provides a new therapeutic paradigm for the long-term weight management of individuals with obesity or overweight.

In addition, once-monthly bofanglutide treatment maintained improvements in cardiometabolic parameters, including waist circumference, blood pressure, and lipid levels.

Bofanglutide demonstrated a favorable safety and tolerability profile across all dose groups, with no new safety signals identified. The most common adverse events during treatment were gastrointestinal adverse events in nature, most of which were mild to moderate in severity and transient.

Detailed results from GRADUAL-3 are planned for presentation at future scientific conferences and publication in international peer-reviewed journals.

SOURCE Gan & Lee Pharmaceuticals

来源:PR Newswire 健康 · prnewswire.com